Matches in SemOpenAlex for { <https://semopenalex.org/work/W2415830264> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2415830264 endingPage "6" @default.
- W2415830264 startingPage "6" @default.
- W2415830264 abstract "Glaucoma is a chronic ophthalmic condition affecting approximately 15 million people. Several therapies are currently available (eg, beta-blockers, sympathomimetics, carbonic anhydrase inhibitors) but have side effects that may limit use. Over the last few years, new medications with improved efficacy and side-effect profiles have become available. This analysis evaluates 2 therapies, brimonidine and betaxolol, based on head-to-head clinical trial data to determine clinical consequences and their related expected costs.To calculate comparative costs and the cost-effectiveness of brimonidine 0.2% and betaxolol 0.25% as first-line therapy for patients with primary open-angle glaucoma.Safety, efficacy, effectiveness, and quality-of-life data were collected in a multicenter, randomized, double-blind, head-to-head comparative effectiveness study, with a drug switch possibility. A disease-intervention model (decision tree) was developed with clinicians, academicians, and health economists. Components of care for each pathway in the model were identified and evaluated; their costs were applied at appropriate points throughout the tree. Expected outcomes and costs were computed and compared.Participants were men (n = 76) and women (n = 112), 21 years of age or older, with newly diagnosed or currently untreated ocular hypertension or open-angle glaucoma.The clinical success rates of first-line brimonidine 0.2% and betaxolol 0.25% are 73.9% and 56.2%, respectively, as determined in a head-to-head comparative effectiveness trial. Total expected costs for patients receiving brimonidine and betaxolol as a primary therapy are $301.37 and $328.19, respectively, based on the model. Dividing costs by outcomes, the cost-effectiveness ratios for brimonidine and betaxolol are $407.81 ($301.37/0.739) and $583.97 ($328.19/0.562), respectively, representing the cost/unit outcome, or the cost to achieve clinical success.Brimonidine 0.2% is less costly and more cost-effective than betaxolol 0.25% when used as initial monotherapy with and without subsequent add-on therapies, including laser treatments and/or surgery, as needed." @default.
- W2415830264 created "2016-06-24" @default.
- W2415830264 creator A5008623230 @default.
- W2415830264 creator A5027519172 @default.
- W2415830264 creator A5061487629 @default.
- W2415830264 creator A5079343112 @default.
- W2415830264 date "2001-07-26" @default.
- W2415830264 modified "2023-09-27" @default.
- W2415830264 title "Clinical and economic impact of new trends in glaucoma treatment." @default.
- W2415830264 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11549985" @default.
- W2415830264 hasPublicationYear "2001" @default.
- W2415830264 type Work @default.
- W2415830264 sameAs 2415830264 @default.
- W2415830264 citedByCount "9" @default.
- W2415830264 countsByYear W24158302642012 @default.
- W2415830264 crossrefType "journal-article" @default.
- W2415830264 hasAuthorship W2415830264A5008623230 @default.
- W2415830264 hasAuthorship W2415830264A5027519172 @default.
- W2415830264 hasAuthorship W2415830264A5061487629 @default.
- W2415830264 hasAuthorship W2415830264A5079343112 @default.
- W2415830264 hasConcept C112930515 @default.
- W2415830264 hasConcept C118487528 @default.
- W2415830264 hasConcept C126322002 @default.
- W2415830264 hasConcept C159110408 @default.
- W2415830264 hasConcept C168563851 @default.
- W2415830264 hasConcept C177713679 @default.
- W2415830264 hasConcept C2778073030 @default.
- W2415830264 hasConcept C2778190193 @default.
- W2415830264 hasConcept C2778527774 @default.
- W2415830264 hasConcept C2779938033 @default.
- W2415830264 hasConcept C2779951463 @default.
- W2415830264 hasConcept C2991803831 @default.
- W2415830264 hasConcept C3019080777 @default.
- W2415830264 hasConcept C535046627 @default.
- W2415830264 hasConcept C71924100 @default.
- W2415830264 hasConceptScore W2415830264C112930515 @default.
- W2415830264 hasConceptScore W2415830264C118487528 @default.
- W2415830264 hasConceptScore W2415830264C126322002 @default.
- W2415830264 hasConceptScore W2415830264C159110408 @default.
- W2415830264 hasConceptScore W2415830264C168563851 @default.
- W2415830264 hasConceptScore W2415830264C177713679 @default.
- W2415830264 hasConceptScore W2415830264C2778073030 @default.
- W2415830264 hasConceptScore W2415830264C2778190193 @default.
- W2415830264 hasConceptScore W2415830264C2778527774 @default.
- W2415830264 hasConceptScore W2415830264C2779938033 @default.
- W2415830264 hasConceptScore W2415830264C2779951463 @default.
- W2415830264 hasConceptScore W2415830264C2991803831 @default.
- W2415830264 hasConceptScore W2415830264C3019080777 @default.
- W2415830264 hasConceptScore W2415830264C535046627 @default.
- W2415830264 hasConceptScore W2415830264C71924100 @default.
- W2415830264 hasIssue "4" @default.
- W2415830264 hasLocation W24158302641 @default.
- W2415830264 hasOpenAccess W2415830264 @default.
- W2415830264 hasPrimaryLocation W24158302641 @default.
- W2415830264 hasRelatedWork W133388262 @default.
- W2415830264 hasRelatedWork W1486779434 @default.
- W2415830264 hasRelatedWork W1964508158 @default.
- W2415830264 hasRelatedWork W2057831528 @default.
- W2415830264 hasRelatedWork W2319301568 @default.
- W2415830264 hasRelatedWork W2415830264 @default.
- W2415830264 hasRelatedWork W3134300556 @default.
- W2415830264 hasRelatedWork W3150965925 @default.
- W2415830264 hasRelatedWork W4246927476 @default.
- W2415830264 hasRelatedWork W842042628 @default.
- W2415830264 hasVolume "3" @default.
- W2415830264 isParatext "false" @default.
- W2415830264 isRetracted "false" @default.
- W2415830264 magId "2415830264" @default.
- W2415830264 workType "article" @default.